Related Experiment Video
Updated: Jul 6, 2025
04:38
A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
Published on: May 22, 2019
10.3K
A comprehensive overview of post-stroke depression treatment options
Alberto Raggi1, Alessandro Serretti2, Raffaele Ferri3
1Unit of Neurology, G.B. Morgagni - L. Pierantoni Civic Hospital, Forlì.
International Clinical Psychopharmacology
|January 3, 2024
Summary
Post-stroke depression (PSD) affects nearly one-third of stroke survivors, impacting recovery. This review explores pharmacological and innovative non-pharmacological treatments to improve outcomes for depression after stroke.
Area of Science:
- Neurology
- Psychiatry
- Rehabilitation Medicine
Background:
- Post-stroke depression (PSD) is a common complication, affecting up to one-third of stroke survivors.
- PSD is linked to poorer functional recovery and overall outcomes following a stroke.
- Effective management strategies are crucial for improving the quality of life for stroke patients.
Approach:
- This narrative review synthesizes current pharmacological and non-pharmacological treatment options for PSD.
- It examines the evidence for selective serotonin reuptake inhibitors (SSRIs) in managing PSD symptoms.
- The review also explores emerging therapies, including cognitive-behavioral therapy, virtual reality, telehealth, and repetitive transcranial magnetic stimulation.
Key Points:
- Selective serotonin reuptake inhibitors (SSRIs) are established treatments for post-stroke depression.
- Innovative approaches like cognitive-behavioral therapy, virtual reality, and neuromodulation show promise.
- These novel therapies may offer enhanced depression treatment for stroke survivors.
- Further high-quality randomized controlled trials are needed to validate these findings.
Conclusions:
- Post-stroke depression requires effective treatment strategies.
- Pharmacological and emerging non-pharmacological therapies offer viable options for managing PSD.
- Continued research is essential to optimize the treatment of depression in stroke survivors.
More Related Videos
04:29Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
28.6K
08:54Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
271
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
239
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
239
01:25Antidepressant Drugs: Overview
503
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
503
01:30Electroconvulsive Therapy
41
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
398
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
398
01:18Depression: Overview
248
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
248
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195